Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of C1013G/CXCR4-associated waldenstroöm's macroglobulinemia with an anti-CXCR4 antibody

Treatment of C1013G/CXCR4-associated waldenstroöm's macroglobulinemia with an anti-CXCR4 antibody

US Patent 10233248 · Granted Mar 19, 2019

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Proteolysis targeting chimeric molecules (PROTACs) with functional handles and u2024
Human monoclonal antibodies that bind CXCR4 and uses thereof2022
Treatment of C1013G/CXCR4-associated Waldenstrom's macroglobulinemia with an ant2022
Treatment of C1013G/CXCR4-associated Waldenstrom's macroglobulinemia with an ant2022
Treatment of C1013G/CXCR4-associated Waldenstrom's macroglobulinemia with an ant2022
Treatment of C1013G/CXCR4-associated Waldenstrom's macroglobulinemia with an ant2022
Genetic abnormalities in plasma cell dyscrasias2021
Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibod2021
Interferon receptor 1 antibodies and their uses2021
Monoclonal antibodies to programmed death 1 (PD-1)2019
Treatment of hematologic malignancies with an anti-CXCR4 antibody2019
Interferon receptor 1 antibodies and their uses2019